UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of February 2026

Commission file number: 001-41523

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On February 24, 2026, Regentis Biomaterials Ltd. issued a press release entitled “Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated February 24, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.

Date: February 24, 2026	By:	/s/ Ehud Geller
	Name:	Ehud Geller
	Title:	Chairman and Chief Executive Officer

REGENTIS BIOMATERIALS LTD. 6-K